On Nov 05, major Wall Street analysts update their ratings for $Glaukos (GKOS.US)$, with price targets ranging from $140 to $149.
J.P. Morgan analyst Allen Gong maintains with a buy rating, and adjusts the target price from $130 to $145.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $145.
Needham analyst David Saxon maintains with a buy rating, and adjusts the target price from $137 to $149.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $139 to $140.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and maintains the target price at $140.
Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:
Glaukos' Q3 outcomes surpassed consensus forecasts with iDose generating $8.8M in conjunction with a 12.3% increase in the iStent infinite and the broader iStent range within the U.S. market. Additionally, the company's Glaucoma business is expanding steadily, achieving growth of over 20% internationally.
Glaukos' third quarter sales surpassed consensus forecasts, fueled by the performance of iDose and OUS MIGS. Following this, management increased their sales guidance by $5 million at the midpoint, corresponding to the scale of the outperformance. There is positive momentum anticipated for iDose continuing into the fourth quarter and towards 2025.
Here are the latest investment ratings and price targets for $Glaukos (GKOS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月5日，多家华尔街大行更新了$Glaukos (GKOS.US)$的评级，目标价介于140美元至149美元。
摩根大通分析师Allen Gong维持买入评级，并将目标价从130美元上调至145美元。
富国集团分析师Larry Biegelsen维持买入评级，维持目标价145美元。
Needham分析师David Saxon维持买入评级，并将目标价从137美元上调至149美元。
BTIG分析师Ryan Zimmerman维持买入评级，并将目标价从139美元上调至140美元。
派杰投资分析师Matthew O'Brien维持买入评级，维持目标价140美元。
此外，综合报道，$Glaukos (GKOS.US)$近期主要分析师观点如下：
Glaukos的第三季度业绩超过共识预测，其中iDose在美国市场上表现出色，实现了880万美元的销售额，与iStent infinite和更广泛的iStent区间一起实现了12.3%的增长。此外，公司的青光眼业务在国际上稳步扩张，实现了超过20%的增长。
Glaukos的第三季度销售额超过共识预测，得益于iDose和OUS MIGS的表现。随后，管理层将销售预期提高了500万美元至中点，与超额业绩规模相对应。预计iDose在第四季度及2025年将继续保持积极动力。
以下为今日5位分析师对$Glaukos (GKOS.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
